+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Tositumomab and 131I tositumomab



Tositumomab and 131I tositumomab



Nature Biotechnology: 0




(PDF emailed within 1 workday: $29.90)

Accession: 018187345

Download citation: RISBibTeXText


Related references

Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma. An oncologist's view. Quarterly Journal of Nuclear Medicine and Molecular Imaging 48(4): 305-316, 2005

Observational Retrospective Study of Altered Biodistribution of Tositumomab and 131I-Tositumomab. Journal of Nuclear Medicine 56(11): 1800-1803, 2016

Essential role of nuclear medicine technology in tositumomab and 131I-tositumomab therapeutic regimen for non-Hodgkin's lymphoma. Journal of Nuclear Medicine Technology 34(2): 67-73; Quiz 74-6, 2006

Long-term results of a randomized trial comparing Tositumomab and Iodine-131 Tositumomab with Tositumomab alone in patients with relapsed or refractory low-grade. Blood 102(11): 405a-406a, November 16, 2003

Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. Oncotargets and Therapy 2: 229-242, 2009

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 22(8): 1469-1479, 2004

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. Journal of Clinical Oncology 23(24): 5696-5704, 2005

Radioimmunotherapy with tositumomab and iodine-131 tositumomab for low-grade non-Hodgkin lymphoma: nursing implications. Oncology Nursing Forum 31(6): 1119-1126, 2004

Re-treatment with Tositumomab and Iodine I 131 Tositumomab therapeutic regimen in patients with non-Hodgkins lymphoma. Blood 102(11): 407a, November 16, 2003

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer 106(3): 616-622, 2005

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. Journal of Clinical Oncology 23(31): 7985-7993, 2005

Rituximab Treatment Failures Tositumomab and Iodine I 131 Tositumomab Can Produce Meaningful Durable Responses. Blood 100(11): Abstract No 1385, November 16, 2002

Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Molecular Imaging and Biology 19(3): 429-436, 2016

Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab. Leukemia and Lymphoma 56(3): 779-781, 2016

Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. Journal of Clinical Oncology 23(4): 712-719, 2004